|
PSCI-24-054 |
Integration of CSF proteogenomics in the diagnosis and management of diffuse gliomas |
|
PSCI-24-077 |
A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor |
|
PSCI-24-079 |
NRG-GU013: The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer |
|
PSCI-24-081 |
Exploring Factors Associated with Understanding Among Head and Neck Surgery Patients |
|
PSCI-24-090 |
Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies for Relapsed Leukemias |
|
PSCI-24-095 |
AHOD2131 A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma |
|
PSCI-24-096 |
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma |
|
PSCI-24-105 |
BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors |
|
PSCI-24-106-A-MM10A-EA02 |
A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial |
|
PSCI-24-106-B-MM1YA-CTG01 |
MM1YA-CTG01 A Measurable Residual Disease (MRD) Focused, Phase II Study Of Venetoclax Plus Chemotherapy For Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 Myelomatch Clinical Trial |
